-transparent.png){kind=logo}
The paucity of studies on the tricyclic antidepressants led us to conduct an investigation on 30 drug-free patients treated with amitryptyline in a double-blind protocol over a 4-week period. Consistent with previous reports, there was an immediate REM suppression on 50 mg, which was more pronounced at the 100-mg level. However, no significant incremental changes were noticed on 150 or 200 mg with regard to REM sleep suppression. Drug administration was associated with changes in other sleep variables such as stage 1 percent, stage 2 percent, and various measures of sleep continuity. The incomplete tolerance of the drug on certain REM sleep variables enhances our understanding of amitryptyline effects on the EEG sleep of depressed patients.
D J Kupfer, and
D G Spiker, and
P Coble, and
R J McPartland
January 1985,
Psychopharmacology,
D J Kupfer, and
D G Spiker, and
P Coble, and
R J McPartland
January 1982,
Advances in biochemical psychopharmacology,
D J Kupfer, and
D G Spiker, and
P Coble, and
R J McPartland
June 1979,
Psychopharmacology,
D J Kupfer, and
D G Spiker, and
P Coble, and
R J McPartland
September 1983,
The American journal of psychiatry,
D J Kupfer, and
D G Spiker, and
P Coble, and
R J McPartland
January 1991,
The Journal of neuropsychiatry and clinical neurosciences,
D J Kupfer, and
D G Spiker, and
P Coble, and
R J McPartland
May 1987,
The American journal of psychiatry,
D J Kupfer, and
D G Spiker, and
P Coble, and
R J McPartland
March 1989,
Biological psychiatry,
D J Kupfer, and
D G Spiker, and
P Coble, and
R J McPartland
October 1991,
Biological psychiatry,
D J Kupfer, and
D G Spiker, and
P Coble, and
R J McPartland
December 1965,
Archives of general psychiatry,
D J Kupfer, and
D G Spiker, and
P Coble, and
R J McPartland
February 2005,
Sleep,
